期刊
VIRUSES-BASEL
卷 9, 期 8, 页码 -出版社
MDPI AG
DOI: 10.3390/v9080229
关键词
HPV; persistent infection; cervical cancer; therapeutics; vaccines; episome maintenance; E2 protein
类别
资金
- National Institutes of Health (NIH) [R01CA187718]
- NCI Cancer Center Support Grant [NCI P30 CA016520]
While the majority of Human papillomavirus (HPV) infections are transient and cleared within a couple of years following exposure, 10-20% of infections persist latently, leading to disease progression and, ultimately, various forms of invasive cancer. Despite the clinical efficiency of recently developed multivalent prophylactic HPV vaccines, these preventive measures are not effective against pre-existing infection. Additionally, considering that the burden associated with HPV is greatest in regions with limited access to preventative vaccination, the development of effective therapies targeting persistent infection remains imperative. This review discusses not only the mechanisms underlying persistent HPV infection, but also the promise of immunomodulatory therapeutic vaccines and small-molecular inhibitors, which aim to augment the host immune response against the viral infection as well as obstruct critical viral-host interactions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据